Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

B Cells and Tertiary Lymphoid Structures : Friends or Foes in Cancer Immunotherapy?

Lauss, Martin LU ; Donia, Marco ; Svane, Inge Marie and Jönsson, Göran LU (2022) In Clinical Cancer Research 28(9). p.1751-1758
Abstract

Tumor cells pose a challenge to the adaptive immune system, and its key cell types, T and B cells, have frequently been associated with an improved prognosis. The success of immune checkpoint blockade has confirmed the relevance of T cells. However, the role of B cells is increasingly recognized, and highlighted in this review. Recent data suggest that tumors contain a diverse set of B cells reflecting different developmental states and exerting functions such as antigen presentation, antibody production, and regulatory effects. Further, B cells are frequently located in tertiary lymphoid structures (TLS), which are immune cell niches that sustain an immune response at sites of chronic inflammation. TLSs in tumors display substantial... (More)

Tumor cells pose a challenge to the adaptive immune system, and its key cell types, T and B cells, have frequently been associated with an improved prognosis. The success of immune checkpoint blockade has confirmed the relevance of T cells. However, the role of B cells is increasingly recognized, and highlighted in this review. Recent data suggest that tumors contain a diverse set of B cells reflecting different developmental states and exerting functions such as antigen presentation, antibody production, and regulatory effects. Further, B cells are frequently located in tertiary lymphoid structures (TLS), which are immune cell niches that sustain an immune response at sites of chronic inflammation. TLSs in tumors display substantial heterogeneity, ranging from cell aggregates to mature structures with an active germinal center. Recent studies have provided insights into initiation, cellular and spatial composition, and function of TLS in a variety of cancer types; however, several critical issues still need to be resolved. Currently, initial reports are discerning the role of TLSs in immunotherapy, with the majority of studies observing TLSs to confer favorable patient outcome. Finally, TLS induction in tumors is evaluated, with the therapeutic aim to reactivate the host immune response.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Cancer Research
volume
28
issue
9
pages
8 pages
publisher
American Association for Cancer Research
external identifiers
  • scopus:85125582157
  • pmid:34965949
ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-21-1130
language
English
LU publication?
yes
id
299f80cf-54f0-48fe-b0e9-09552156ecd8
date added to LUP
2022-12-30 10:14:58
date last changed
2024-06-24 07:26:58
@article{299f80cf-54f0-48fe-b0e9-09552156ecd8,
  abstract     = {{<p>Tumor cells pose a challenge to the adaptive immune system, and its key cell types, T and B cells, have frequently been associated with an improved prognosis. The success of immune checkpoint blockade has confirmed the relevance of T cells. However, the role of B cells is increasingly recognized, and highlighted in this review. Recent data suggest that tumors contain a diverse set of B cells reflecting different developmental states and exerting functions such as antigen presentation, antibody production, and regulatory effects. Further, B cells are frequently located in tertiary lymphoid structures (TLS), which are immune cell niches that sustain an immune response at sites of chronic inflammation. TLSs in tumors display substantial heterogeneity, ranging from cell aggregates to mature structures with an active germinal center. Recent studies have provided insights into initiation, cellular and spatial composition, and function of TLS in a variety of cancer types; however, several critical issues still need to be resolved. Currently, initial reports are discerning the role of TLSs in immunotherapy, with the majority of studies observing TLSs to confer favorable patient outcome. Finally, TLS induction in tumors is evaluated, with the therapeutic aim to reactivate the host immune response.</p>}},
  author       = {{Lauss, Martin and Donia, Marco and Svane, Inge Marie and Jönsson, Göran}},
  issn         = {{1078-0432}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{9}},
  pages        = {{1751--1758}},
  publisher    = {{American Association for Cancer Research}},
  series       = {{Clinical Cancer Research}},
  title        = {{B Cells and Tertiary Lymphoid Structures : Friends or Foes in Cancer Immunotherapy?}},
  url          = {{http://dx.doi.org/10.1158/1078-0432.CCR-21-1130}},
  doi          = {{10.1158/1078-0432.CCR-21-1130}},
  volume       = {{28}},
  year         = {{2022}},
}